The Latest GLP-1 Oral Medication, Foundayo: What Employers Need to Know 

Exciting news in the obesity care community! On April 1, 2026, the FDA approved Eli Lilly's oral medication Foundayo (orforglipron) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It starts shipping this week.

Lilly’s Foundayo joins two existing oral GLP-1 options from Novo Nordisk. Novo’s formulations are (1) oral Wegovy, a higher dose of semaglutide approved for obesity treatment, and (2) Rybelsus (rebranding shortly as oral Ozempic) which is lower in dose and approved for type 2 diabetes.

For employers managing GLP-1 benefits for obesity, you may be wondering what all the buzz is about, and what it could mean for the health of your members. You may also be wondering what it may mean for your bottom line. 

What Do the Weight Loss Numbers Look Like?

While there aren’t any direct heat-to-head trials comparing oral Wegovy to Foundayo, in the available clinical trial data we see the following:

• Oral Wegovy resulted in 16.6% weight loss over 64 weeks.
• Foundayo demonstrated 12.4% weight loss over 72 weeks.
• Side effects were similar between oral Wegovy and Foundayo and included nausea along with other GI disturbances, fatigue, and headache.

While Foundayo’s trial results don’t seem as compelling as oral Wegovy or the injectable GLP-1s, it’s still a key addition to the GLP-1 lineup. This is because significant clinical improvements in things like blood glucose, blood pressure, energy, and pain scores can be seen with as little as 5% weight loss. There’s also 11% fewer strokes and 6% fewer heart attacks, all translating into better health, quality of life, and measurable cost savings for employers .

Why Foundayo Could Drive Broader Adoption

Besides the clinically relevant 5% weight loss, Foundayo’s approval is a meaningful advance that could drive much broader adoption of the med. Here’s why:

• Even though injectable GLP-1s still lead on clinical efficacy (15 and 20% weight loss with Wegovy and Zepbound respectively) and dominate the market to date, there’s a segment of patients who would prefer an oral option over self-injections. This segment of patients may prioritize convenience and tolerability, and/or have more modest weight loss goals. 
• Unlike Novo Nordisk's oral Wegovy tablet which is a peptide molecule, Foundayo is a small-molecule pill that can be taken any time of day, with or without food or water restrictions. The Wegovy tablet, by contrast, requires morning dosing on an empty stomach with a waiting period prior to eating or drinking. This is a constraint that could substantially limit Wegovy’s uptake and adherence. Therefore, by removing that friction, Foundayo may expand patient willingness to start treatment - a huge upside.
• The small-molecule Foundayo pill is easier and less costly to manufacture than an oral peptide, meaning that medication access concerns are less likely to surface.
• Foundayo’s less costly manufacturing costs will (I hope!) translate into lower prices for consumers, making Foundayo more palatable as a long-term medication.

What This Means for Your Workforce

Foundayo can potentially impact two distinct employee populations. 

The first population comprises current injectable GLP-1 users who may prefer switching to a pill. Early signals are already emerging: on the morning of Foundayo's approval, Calibrate clinicians immediately noted calls from members on injectable GLP-1s asking about transitioning to orals. 

The second and much larger population includes people who have never taken GLP-1s. For these individuals, the pill format and dosing freedom removes significant practical and psychological barriers to entry. It’s easy to see that this is the population likely to drive the largest cost burden for employers.

Calibrate's Take

Broader access to GLP-1 medications is genuinely wonderful news for population health. But easier access alone isn’t a sustainable solution to obesity. 

Without strong member support and a quality clinical oversight framework in place, employers risk:

• Unpredictable pharmacy spend
• Inconsistent adherence
• Weight regain and the associated clinical and occupational consequences

In other words, Foundayo changes the scale of the opportunity we have to treat obesity, as well as the urgency of the employer response. 

The question is no longer whether your employees will seek GLP-1 coverage. It's whether you have the clinical governance framework in place to ensure your employees are getting the right medication for their unique needs, that treatment delivers lasting results, and that the spend remains controlled and justified.

Ready to build a clinically accountable GLP-1 benefit?

Calibrate is the only clinically validated weight management program proven to deliver 20% average weight loss sustained over three years. 

Talk to our team to learn how Calibrate helps employers govern GLP-1 spend and deliver outcomes that last.

Contact us at calibratehealth.com/